- Investing Ideas
- /
- Taiwanese Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Taiwanese Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
6
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
6 companies
Lotus Pharmaceutical
Market Cap: NT$57.8b
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
1795
NT$225.00
7D
1.4%
1Y
-4.5%
TTY Biopharm
Market Cap: NT$19.2b
Engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally.
4105
NT$77.40
7D
0.7%
1Y
8.3%
Synmosa Biopharma
Market Cap: NT$19.0b
A specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan.
4114
NT$37.90
7D
3.8%
1Y
17.7%
Formosa Laboratories
Market Cap: NT$8.1b
Manufactures and sells active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally.
4746
NT$71.00
7D
5.5%
1Y
-20.2%
Chi Sheng Pharma & Biotech
Market Cap: NT$1.8b
Engages in the manufacturing, processing, sale, and import and export trade of pharmaceuticals, medical products, cosmetics, health foods, and medical equipment in Taiwan and internationally.
4111
NT$32.05
7D
0.3%
1Y
25.4%
BioLASCO Taiwan
Market Cap: NT$873.4m
Provides bio-materials and surgical services in Taiwan and internationally.
6662
NT$34.10
7D
0.9%
1Y
-7.3%